GLP-1 Activity
helps regulate hunger and satiety, supports glucose-dependent insulin secretion, reduces glucagon signaling, and may slow gastric emptying.
$499.00
An orally disintegrating tablet designed to support appetite control, weight management, glucose regulation, and metabolic health.
May support appetite control: Targets pathways involved in hunger and satiety.
May support weight management: May help reduce appetite and overall food intake.
May support Dual GIP + GLP-1 activity: Targets two complementary incretin pathways involved in metabolic health.
Needle-free option: Orally disintegrating tablet designed to dissolve under the tongue.
Tirzepatide carries a boxed warning regarding the risk of thyroid C-cell tumors observed in animal studies.
Tirzepatide is contraindicated in patients with:
Additional clinical considerations may include:
Review your medical history, medications, and supplements with your prescribing clinician before treatment. Because this is a compounded oral formulation, follow the dosing and administration instructions specifically provided with your prescription.
Commonly reported side effects may include:
Individual response and tolerability can vary.
ODT stands for orally disintegrating tablet. It is designed to dissolve rather than being swallowed like a conventional tablet.
No. This compounded Tirzepatide ODT formulation is not FDA-approved. FDA-approved tirzepatide medications are available in injectable formulations. This compounded oral formulation is distinct and should not be considered interchangeable with FDA-approved tirzepatide products.
Tirzepatide activates GIP and GLP-1 receptors involved in hunger, satiety, insulin response, and metabolic signaling. Its effects on appetite may help reduce food intake as part of a clinician-directed weight-management program.
No. Tirzepatide ODT is an orally disintegrating tablet, providing a needle-free option for a clinician-directed compounded tirzepatide protocol.
No. The formulation, route of administration, absorption, concentration, and dosing differ. Do not substitute one formulation for another unless directed by your prescribing clinician.
Yes, a compounded tirzepatide prescription may be provided through telehealth when a licensed clinician determines treatment is medically appropriate and applicable prescribing and compounding requirements are met.
Tirzepatide ODT is a compounded orally disintegrating tablet containing tirzepatide, a medication that activates both GIP and GLP-1 receptors involved in appetite, glucose regulation, insulin response, and metabolic signaling.
The ODT formulation provides a needle-free oral option for clinician-directed weight-management and metabolic-health protocols.
This compounded oral formulation is not FDA-approved and is distinct from FDA-approved injectable tirzepatide products.
All dosing should follow the instructions provided by the prescribing clinician.
Tirzepatide activates GIP and GLP-1 receptors, two incretin hormone pathways involved in appetite, glucose regulation, insulin response, and metabolic function.
helps regulate hunger and satiety, supports glucose-dependent insulin secretion, reduces glucagon signaling, and may slow gastric emptying.
supports glucose-dependent insulin response and nutrient-related metabolic signaling.
Together, this dual GIP + GLP-1 activity can help reduce appetite and food intake while supporting glucose regulation and overall metabolic health.
The ODT formulation provides a needle-free oral option for clinician-directed weight-management and metabolic-health protocols.
Tirzepatide belongs to a class of medications known as dual GIP and GLP-1 receptor agonists.
Treatment eligibility is determined through an individualized medical evaluation. Compounded Tirzepatide ODT is not itself FDA-approved.
All dosing should follow the instructions provided by the prescribing clinician.
